Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
目前提供的是
吲哚氧化酶
抑制剂前药和盐类化合物,以及包含
吲哚氧化酶
抑制剂前药和盐类的药物组合物,相比直接给予
吲哚氧化酶
抑制剂,这些组合物在需要治疗由
吲哚胺-2,3-二氧化酶途径介导的免疫抑制的患者中,如癌症或慢性传染病患者,能够产生增强的血浆浓度和暴露于
吲哚氧化酶
抑制剂。